Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03502681
Title A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Monika Joshi, MD

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma


Avelumab + Eribulin

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.